Baumann G, Ningel K, Vieweg J, Joder-Ohlenbusch A M, Cremer G
First Department of Medicine, Klinikum Rechts der Isar, University of Munich, Germany.
Eur Heart J. 1991 Apr;12(4):533-40. doi: 10.1093/oxfordjournals.eurheartj.a059935.
Four intravenous doses of piroximone, an imidazolone derivative, were administered to 12 patients with congestive heart failure to produce a four-point dose-response curve. The haemodynamic effects were compared with those of dobutamine and nitroprusside, the substances being given sequentially and in randomized order. Piroximone and dobutamine significantly and similarly increased cardiac index (CI) and stroke volume index (SVI). Nitroprusside produced no such effect. By contrast, piroximone and nitroprusside significantly and similarly decreased mean pulmonary artery pressure (MPAP), pulmonary capillary wedge pressure (PCWP), right atrial pressure (RAP) and pulmonary vascular resistance (PVR), while such changes were not seen following dobutamine. Direct comparisons between the agents were made at doses that lowered systemic vascular resistance (SVR) to the same extent. The major difference between dobutamine and piroximone was an apparent additional vasodilator activity displayed by piroximone as demonstrated by a significantly greater decrease in MPAP, PCWP and RAP for a matched reduction in SVR and a similar increase in CI. The major difference between nitroprusside and piroximone was the significantly higher increase in CI and SVI elicited by piroximone for a matched reduction in SVR and a similar decrease in PCWP and RAP. The changes in loading conditions being equivalent, the higher increase in CI is likely to be accounted for by a direct inotropic activity.
对12例充血性心力衰竭患者静脉注射4剂吡罗昔酮(一种咪唑啉酮衍生物),以绘制四点剂量反应曲线。将血流动力学效应与多巴酚丁胺和硝普钠的效应进行比较,这些药物按随机顺序依次给药。吡罗昔酮和多巴酚丁胺显著且相似地增加了心脏指数(CI)和每搏量指数(SVI)。硝普钠没有产生这种效果。相比之下,吡罗昔酮和硝普钠显著且相似地降低了平均肺动脉压(MPAP)、肺毛细血管楔压(PCWP)、右心房压(RAP)和肺血管阻力(PVR),而多巴酚丁胺给药后未出现此类变化。在使体循环血管阻力(SVR)降低到相同程度的剂量下对这些药物进行直接比较。多巴酚丁胺和吡罗昔酮之间的主要差异在于,吡罗昔酮表现出明显的额外血管舒张活性,这表现为在SVR匹配降低且CI类似增加的情况下,MPAP、PCWP和RAP显著更大程度的降低。硝普钠和吡罗昔酮之间的主要差异在于,在SVR匹配降低且PCWP和RAP类似降低的情况下,吡罗昔酮引起的CI和SVI显著更高的增加。在负荷条件变化相当的情况下,CI的更高增加可能是由直接的正性肌力活性所致。